ArticleCerebellum (London, England)2025
Novel KIF1A Variant in a Patient with Cerebellar Atrophy and Ataxia: A Case Report.
Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "I felt like a lone ranger": experiences of Australian families living with KIF1A-Associated Neurological Disorder.Journal of community genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic variants in KIF1A are associated with a spectrum of neurological disorders collectively known as KIF1A-associated neurological disorders (KAND). We present the case of a 57-year-old female with lifelong dysarthria, gait instability, and progressive ataxia, diagnosed with cerebellar ataxia in her late 40s. Brain MRI revealed diffuse cerebellar atrophy. Genetic testing identified a novel heterozygous KIF1A (NM_004321.6) variant, c.1788_1790delinsACG (p.His596_Pro597delinsGlnArg), which is absent from population databases and predicted to be deleterious by multiple in silico tools. Unlike most pathogenic KIF1A variants that cluster within the motor domain, this variant lies outside this region. In silico structural modeling suggests this substitution likely affects local protein architecture through two concurrent changes: the substitution of histidine 596 with glutamine represents a modest change to the local biochemical environment, while the replacement of the conformationally restrictive proline 597 with arginine removes the characteristic cyclic structure that constrains the peptide backbone. Family history was notable for cerebellar atrophy in the mother and similar neurological symptoms in the maternal brother, suggesting possible autosomal dominant inheritance. The identification of this novel KIF1A variant outside the motor domain expands our understanding of KAND's genetic basis and suggests that non-motor domain variants may be associated with slowly progressive neurological symptoms.
Indexed as
Identifiers
40198464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.